CardiologyacoramidisATTR-CM
Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis
By MedXY|Apr 2, 2026
This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintai